Pfizer On Reorganizing, M&A And Investing In Internal R&D
Executive Summary
The big pharma's leadership weighs in on why it made sense to organize biosimilars under innovative medicines, why it is investing more in internal R&D, and why tuck-in deals are more appealing than transformative M&A.
You may also be interested in...
At Pfizer, A Split A Decade In The Making
Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.
BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says
BioMarin’s focus on rare diseases and gene therapies and expected financial growth make it a logical acquisition target for almost any large pharma, though Biogen, Amgen and Regeneron also offer a beneficial fit for many.
Keeping Track: FDA Starts November With A Bang
The latest drug development news and highlights from our FDA Performance Tracker.